Syk-Targeted, a New 3-Arylbenzofuran Derivative EAPP-2 Blocks Airway Inflammation of Asthma–COPD Overlap in vivo and in vitro

Shuyi Li,Yang Hui,Jiqiao Yuan,Ziqian Zhang,Xuyu Li,Nan Fang,Mingbao Lin,Qi Hou

DOI: https://doi.org/10.2147/JIR.S310875

IF: 4.5

2021-05-25

Journal of Inflammation Research

Abstract:Shuyi Li, Yang Hui, Jiqiao Yuan, Ziqian Zhang, Xuyu Li, Nan Fang, Mingbao Lin, Qi Hou Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China Correspondence: Mingbao Lin; Qi Hou Tel +86-10-63165192 ; +86-10-63165191 Email ; Introduction: Asthma–chronic obstructive pulmonary (COPD) overlap (ACO) coexists with asthma and COPD syndrome characteristics, with more frequent exacerbations, heavier disease burden, higher medical utilization, and even lower quality of life. However, the ACO standard medications supported by evidence-based medicine have not yet appeared. Methods: By using an ACO mouse model established previously and LPS-stimulated RAW264.7 macrophages in vitro, a potential therapeutic candidate, EAPP-2, was screened from derivatives of 3-arylbenzofuran, and its effect and mechanism on ACO inflammation were evaluated. Results: EAPP-2 significantly alleviated airway inflammation in ACO mice and also inhibited the inflammatory reactions in LPS-induced RAW264.7 macrophages in vitro. Furthermore, EAPP-2 significantly inhibited the expression and phosphorylation of spleen tyrosine kinase (Syk), a common target regulating both eosinophils and neutrophils inflammation. In addition to this, EAPP-2 significantly down-regulates the expression of NF-κB, p-NF-κB, and NLRP3 in vivo and in vitro. Moreover, by using specific inhibitors in vitro, it was validated that EAPP-2 targeted on Syk and then regulated its downstream NF-κB and NLRP3. Conclusion: EAPP-2 is shown to be a potentially useful therapeutic candidate for ACO, and its mechanism is at least partially achieved by targeting on Syk and then inhibiting NF-κB or NLRP3. Moreover, this study suggests that Syk may be a potentially effective target for ACO therapy. Keywords: EAPP-2, asthma–COPD overlap, ACO, Syk, NF-κB, NLRP3 Asthma and chronic obstructive pulmonary disease (COPD), two clinical frequently – occurring chronic airway inflammatory diseases, are caused by different inflammatory pathological mechanisms. However, with many similarities in clinical symptoms, sometimes it is hard to diagnose asthma or COPD clearly. Furthermore, a considerable number of patients coexist with the problems of asthma and COPD. So that asthma–COPD overlap (ACO), referring to patients "characterized by persistent airflow limitation with several features usually associated with asthma and several features usually associated with COPD," was used as a "description for clinical use" by the Global Initiative of Asthma (GINA) and the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) in 2017. 1 , 2 In clinical trials, ACO patients have more frequent exacerbations, heavier disease burden, higher medical utilization, and lower quality of life compared to those with asthma and COPD alone. 3–6 However, besides the difficulty to diagnose, there is still a lack of exact specific and effective treatment of ACO. At present, the treatment of suspected ACO is mainly based on the treatment of severe asthma and COPD phenotype guidance, treated with inhaled glucocorticoids (ICS), long-acting β2-agonist (LABA) and long-acting muscarinic antagonists (LAMA). Therefore, looking for specific drugs or methods for ACO treating has become particularly important and urgent. A potential common target of asthma and COPD inflammation may also be an effective target for ACO therapeutic intervention. Syk, a 72kD non-receptor protein tyrosine kinase, widely present in various hematopoietic cells and some non-hematopoietic cells. 7–9 Syk has been proved to be a potential therapeutic target for both asthma and COPD inflammation. 10 , 11 In asthma, Syk is rapidly recruited and activated by FcεRI-mediated signaling pathways in human basophils, leading to cell degranulation and histamine release. 12 And in patients with COPD, Syk is one of the kinases required for neutrophils to form neutrophil extracellular traps (NET). 13 , 14 Furthermore, previously, by using comparative RNA‐Seq transcriptome analysis on pulmonary inflammation in an ACO mouse model, we also found that Syk was a potential mainly affected signaling pathways of inflammation in ACO mouse. 15 Phosphorylated Syk activated via its SH2 domains binds to the dual phosphorylated immunoreceptor tyrosine-based activation motif (ITAM), 16 and its phosphorylated tyrosine residues can be used as anchor po -Abstract Truncated-

immunology